SigInno Therapeutics Secures RMB 80 Million Series A Funding to Advance 'Organoid+AI' Drug Discovery Platform and Global Clinical Development

Shenzhen, China, January 14, 2026 —— Signet Therapeutics, a pioneer in the global "Organoid+AI" empowered innovative targeted drug R&D model, announced today the completion ofRMB 80 million in Series A financing. This round of financing was led byXtalPi, Songhe Capital, Zhisheng Synergy, Tiantu Yiyi Capital, and Blue Ocean Capital jointly invested.The funds will be mainly used to advance the global Phase II clinical trial of the company's first pipeline, SIGX1094, as well as the IND application and Phase I clinical trial of the second pipeline, SIGX2649, further expanding the company's layout in the field of targeted therapy for malignant metastatic solid tumors. In addition to the pipelines, this round of financing will also actively promote the business expansion of the company’s organoid platform in empowering drug innovation and development.

"Organoid + AI" Platform Driven, from Source Innovation to Clinical Validation

Since its establishment in late 2020, SIGNET has been committed to addressing significant unmet clinical needs in diffuse gastric cancer, liver cancer, lung cancer, and other malignant metastatic cancers, with a forward-looking "organoid + AI" drug discovery platform at its core. The company's founding team is composed of senior experts from globally renowned research institutions such as Harvard University's Dana-Farber Cancer Institute, MIT Broad Institute, as well as leading pharmaceutical companies. By establishing unique organoid disease models, the team deeply integrates the real genomic characteristics and functional biology of cancer patients, aiming to address key issues that may arise during the clinical stage in the preclinical phase, thereby systematically improving the efficiency and success rate of new drug development.

Based on this organoid platform, SIGNET has successfully discovered novel therapeutic targets for various cancers. Building on this, SIGNET has entered into a deep strategic partnership with XtalPi (2228.HK), the first company in the "AI + robotics" space, to jointly develop innovative targeted drugs.

The first pipeline of the company, SIGX1094, took less than four years from target discovery to entering Phase I clinical trials. It successively obtained the Investigational New Drug (IND) application approvals from the U.S. FDA (June 2024) and China's NMPA (September 2024), and received the FDA Orphan Drug Designation (ODD, November 2024) and Fast Track Designation (FTD, February 2025). The second pipeline, SIGX2649, is an innovative small-molecule inhibitor targeting TEAD, a key transcription factor in the Hippo pathway, with the potential to treat various solid tumors such as mesothelioma, liver cancer, and lung cancer. Preclinical development has been completed, and preparations are underway for the simultaneous submission of IND applications to regulatory authorities in both the U.S. and China.

SIGNET’s innovative "Organoid + AI" drug discovery paradigm has gained authoritative recognition both in China and internationally. Not only was the company featured on the homepage of the globally renowned biotech media Fierce Biotech as early as 2021, where it was hailed as the "next-generation cancer drug discovery paradigm," but its technological approach also strongly aligns with the 2025 U.S. FDA policy statement supporting the use of organoids and AI technologies as alternatives to traditional animal testing.

In addition, SIGNET has constructed a variety of standardized tumor organoid models based on patient genomic characteristics and gene-editing-induced carcinogenesis to achieve the feasibility of early drug development screening. For instance, the company's self-developed cardiac organoid model, which features atrial and ventricular structures, significantly improves the accuracy of drug cardiotoxicity prediction to approximately 85%. The traditional gold standard for cardiotoxicity testing, "hERG," only reflects potassium ion channel function with a prediction accuracy of about 45%. To address this challenge, the SIGNET team systematically analyzed cardiotoxicity data from over 120 drugs, constructing a beating 3D cardiac organoid model in vitro. By integrating AI technology to intelligently analyze the beating images of the organoids, they increased the accuracy of cardiotoxicity prediction to approximately 85%, providing a more reliable and physiologically relevant solution for preclinical drug safety evaluation. Currently, Signet Therapeutics is the only corporate entity participating in the formulation of organoid standards by the National Medical Products Administration (NMPA) and the National Institutes for Food and Drug Control (NIFDC), continuously promoting industry standards.

Continuous Capital Support Drives Innovation in New Drug Development

Dr. Haisheng Zhang, Founder and CEO of Signet TherapeuticsRepresentation"In the field of targeted therapy for malignant metastatic solid tumors such as diffuse gastric cancer, a large number of patients still face the dilemma of having no available drugs or limited treatment options. Original innovation is our初心 (original aspiration), and we firmly choose the entirely new R&D model of 'organoids + AI,' hoping to start from the essence of the disease and transform cutting-edge science into truly effective treatment solutions. We sincerely thank Songhe Capital, XtalPi, Zhisheng Synergy, TianTu YaYi Capital, and Blue Ocean Capital for their support and trust. We will continue to strengthen our new drug R&D technology platform with the goal of making original innovations from China accessible as treatment options for patients worldwide."

Dr. Shuhao Wen, Chairman of the Board of Directors of XtalPiStated: "As an important strategic partner of Signet Therapeutics since its establishment, XtalPi has been fully involved in and witnessed the innovative drug R&D journey from target discovery to compound optimization. By deeply integrating AI-driven molecular design with organoid models, we have jointly built a precise and efficient R&D closed loop. The success of this novel model has enabled SIGX1094 to not only quickly advance into clinical trials but also receive a nomination for the Galien Award, known as the 'Nobel Prize of the pharmaceutical industry.' This achievement highlights SIGNET's outstanding performance in R&D efficiency and fundamentally validates the tremendous potential of 'AI + organoids' in advancing new drug development. Looking ahead, we look forward to further deepening our cooperation with SIGNET, including empowering cardiac organoid models with AI, revolutionizing safety evaluation methods in drug development, and jointly defining the future of intelligent pharmaceuticals."

Luo Fei, Founding Partner of Pinehurst CapitalRepresentation"As one of the early investors in Signet Therapeutics, PineWood Capital has increased its investment in this round. The core reason is the deep recognition of the company's disruptive new drug R&D system built on the 'Organoid+AI' platform. This end-to-end early validation mechanism significantly reduces the development risks of innovative drugs and greatly enhances R&D efficiency and success rates. SIGNET has not only successfully advanced SIGX1094 from target discovery to the global clinical stage but also preemptively addressed potential clinical issues using organoid models, fully demonstrating the platform's value. This platform not only supports the efficient output of the company’s internal pipeline but also has the potential to set a new standard for preclinical R&D in the industry. It is an exemplary model of China’s original technology achieving a 'lane change surpass' in global biopharmaceutical competition. PineWood Capital will continue to support Signet Therapeutics in driving breakthroughs in targeted therapies for malignant solid tumors worldwide and help China’s original innovative drugs reach the global stage."

Huang Shaojie, Partner of Signet TherapeuticsPoint out"Our investment in Signet Therapeutics is not only a recognition of a verifiable new drug R&D paradigm, but also a high level of trust in the team behind it. The team has not only built the world's first 'organoid + AI' platform, but more importantly, they have demonstrated excellent execution in efficiently converting the platform’s potential into clinical value. The first pipeline, SIGX1094, fills the gap for treating diffuse gastric cancer where no drugs are currently available, and the second pipeline, SIGX2649, as a pan-TEAD inhibitor, shows broad prospects in treating various cancers such as mesothelioma and liver cancer. We believe this mutually reinforcing model of 'platform validation and pipeline output' represents a new direction in biotech innovation, and we are very optimistic about its potential to disrupt the industry."

Wei Guoxing, Partner of TianTu InvestmentStated, "From the early support of SIGNET until now, what we value most is the team's excellent strategic execution and innovative ability to transform scientific discoveries into tangible results. In just a few years, the company has exceeded our expectations at every step, from platform construction to pipeline advancement, and even to receiving national awards and nominations for international highest honors. This efficient and pragmatic style makes us believe that SIGNET has the capability to secure a place in the highly competitive global innovative drug field. Therefore, we continue to increase our investment and accompany the company towards its next milestone."

Yang Feng, Founding Partner and CEO of Blue Ocean Capital"We continue to invest in SIGNET as a strong recognition of the company's leading biotechnologies such as organoids. The continuous technological breakthroughs, clinical milestones, and commercial progress further validate the international vision and core competitiveness of the company’s team. We are optimistic about SIGNET’s long-term development and look forward to the company becoming an innovative biopharmaceutical enterprise with international competitiveness."

SIGNET is a global pioneer in the "organoid + AI"-powered innovative targeted drug R&D model, and is a national high-tech enterprise as well as a specialized and new enterprise. The company's founding team consists of top talents from prestigious institutions such as Harvard University, MIT, and the Chinese Academy of Sciences. As first/corresponding authors, they have published over 20 groundbreaking research papers on gastric cancer, esophageal cancer, and other cancer fields in journals with impact factors exceeding 20, including Nature, Nature Medicine, and Cancer Cell, establishing itself as a global leader in gastric and esophageal cancer research. Since its establishment in Shenzhen at the end of 2020, Signet Therapeutics has completed nearly 300 million yuan in financing and project funding, and holds more than 40 core intellectual properties.

The company currently has four first-in-class drug pipelines and one organoid platform in its portfolio. The core pipeline, SIGX1094, is the world's first targeted drug for diffuse gastric cancer. It has obtained IND approval from both the U.S. FDA and China's NMPA, and received Orphan Drug Designation (ODD) and Fast Track Designation (FTD) from the U.S. FDA. In August 2025, this drug was nominated for the Galien Award, known as the "Nobel Prize of the pharmaceutical industry." It is currently undergoing Phase I clinical trials at the Peking University Cancer Hospital. This pipeline is also the world’s first drug to be advanced into clinical trials through an "organoid + AI" technology platform. The second pipeline, SIGX2649, is a pan-TEAD inhibitor targeting the key downstream effector of the Hippo signaling pathway. There are currently no marketed drugs targeting this site, and an IND application will soon be filed simultaneously in the U.S. and China.